Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

In this special bonus episode Talking General Practice speaks to consultant nephrologist Dr Shafi Malik about the heightened ...

Massachusetts Institute of Technology professor Phillip Sharp co-founded Alnylam with several others in 2002. It wasn't Sharp ...

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...

Investors in Alnylam Pharmaceuticals, Inc. ALNY need to pay close attention to the stock based on moves in the options market ...

An announcement from Alnylam Pharma ( ($ALNY) ) is now available. On December 10, 2025, Alnylam Pharmaceuticals announced it had entered into ...

Alnylam Pharmaceuticals, Inc. ("Alnylam") (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with ...

Leerink analyst Mani Foroohar lowered the firm’s price target on Alnylam to $351 from $370 and keeps a Market Perform rating on the shares. Heading into 2026, the firm is refreshing its TTR market ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of ...

The latest update on Tuesday morning shows Alnylam Pharmaceuticals shares up by 3.84%, trading at $472.0. At this price, ...

Alnylam Pharmaceuticals recently announced past and upcoming Board changes, with long-serving directors Mike Bonney and Carolyn Bertozzi, Ph.D., stepping down and industry veteran Stuart Arbuckle ...